Treatment of Multiple Small Bowel Angiodysplasias Causing Severe Life‐threatening Bleeding With Thalidomide

The role of HIF‐1, angiopoietin‐2, Dll4 and Notch1 in bleeding gastrointestinal vascular malformations and thalidomide‐associated actions: A pilot in vivo study

“…The efficacy of thalidomide in preventing rebleeding from angiodysplasia has previously been reported only in case reports and case series. [9][10][11][12][13][14] In this exploratory study, 10 patients with recurrent GI bleeding due to vascular malformation (VM) received 4-month thalidomide treatments, of whom eight patients (80%) achieved effective response and five (50%) displayed a cessation of bleeding. Furthermore, their transfusion requirements decreased while their hemoglobin increased significantly after thalidomide treatment.…”

“…Thalidomide has recently been reported to be successful in preventing rebleeding from GI angiodysplasia. [9][10][11][12][13][14] However, the precise mechanism of its associated actions has not yet been elucidated.…”

Hemorragia invalidante y recidivante por angiodisplasia intestinal: tratamiento con talidomida

“…Nosotros comenzamos con los análogos de la somatostatina, a las dosis recomendadas (100 µg/12 h s.c.) durante cuatro semanas sin obtener resultado. A la vista de los casos publicados en el tratamiento con talidomida (3)(4)(5)(6)(7)(8), cuyo éxito parece derivar de su efecto antiangiogénico (3,9), decidimos intentar dicha terapia. Hasta el momento, el resultado ha sido más que satisfactorio, con control de su sintomatología, "ahorro" de ingresos hospitalarios y transfusiones sanguíneas y sin efectos secundarios mayores.…”

Thalidomide in angiodysplasia‐related bleeding

“…The number of patients from these reports totalled 70, drawing from one randomised controlled trial with 28 patients on the thalidomide arm, 2 29 patients from five case series 3-7 and 13 single-case reports. [8][9][10][11][12][13][14][15][16][17][18][19][20] Of these patients, six had bleeding diathesestype 2 von Willebrand disease (n = 3), 11,12,16 factor V deficiency (n = 1) 17 and anticoagulation (n = 2) 3,9 while five had hereditary haemorrhagic telangiectasia. 7,8,20 The median age of patients was 65 (range 7-86) with more females (60%).…”